LRRC32

LRRC32

LRRC32 詳細

Molecule Name
Transforming growth factor beta activator LRRC32
分子の別称
GARP,Garpin,D11S833E
Drug Development Progress
治験薬の数7
市販薬剤の数0
研究&開発段階Phase 3 Clinical
ターゲットの別称
Leucine Rich Repeat Containing 32,D11S833E,Garpin,Leucine-Rich Repeat-Containing Protein 32,LRRC32,Transforming Growth Factor Beta Activator LRRC32,GARP,Glycoprotein A Repetitions Predominant
バックグランド
Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells. LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells. The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation.

LRRC32 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
LivmoniplimabMGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115Phase 3 ClinicalArgenx Se
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours
詳細
Anti-GARP Chimeric Antigen Receptor T Cell Therapy (Ohio State University Comprehensive Cancer Center)Phase 1 ClinicalOhio State University Comprehensive Cancer Center
Glioma
詳細
PBA-0111PBA-0111Phase 1 ClinicalPure Biologics SA
Sarcoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
詳細
HLX-6018HLX-6018; HLX6018Phase 1 Clinical
Idiopathic Pulmonary Fibrosis
詳細
JYB-1907JYB-1907Phase 1 ClinicalJiangxi Jemincare Group Co Ltd
Solid tumours
詳細
DS-1055DS-1055; DS-1055aPhase 1 ClinicalDaiichi Sankyo Co Ltd
Neoplasms; Solid tumours
詳細
HLX-60HLX-60Phase 1 Clinical
Lymphoma; Solid tumours
詳細